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Alexandros Spyridonidis,4 Panagiotis Repousis,5 Artemisia Balta,2 Simeon Tsimberis,1
Dimitrios Karakasis,2 Ioanna Sakellari,1 Ioannis Dervenoulas,3 Nicholas Harhalakis,2
Achilles Anagnostopoulos1Patients with relapsed/progressed Hodgkin’s lymphoma (HL) following autologous hematopoietic cell trans-
plantation (AHCT) may not have an invariably dismal outcome as previously considered. In a multicenter ret-
rospective study, we evaluated 126 patients who relapsed/progressed after a median of 5 (1-132) months
post first AHCT. Management consisted of irradiation, chemotherapy 6 irradiation, second HCT, or pallia-
tion. Currently, 53 of 126 (42%) patients are alive for a median of 32 months since relapse/progression and 44
(35%) of them remain progression-free. Interval of\12 months to relapse/progression, presence of B-symp-
toms, and disease refractoriness at first AHCT failure adversely influenced overall survival (P\ .05). The
type of treatment had no impact on survival. Furthermore, to predict the outcome at the time of relapse/
progression, we constructed a prognostic model based on 3 factors: interval of\12 months from first
AHCT to relapse/progression, presence of B-symptoms, and pre-AHCT disease refractoriness. Patients
with 0 to 1 factors achieved a median survival of 70 months compared to 17 months only in those with 2
to 3 factors (P \ .001). This study, the largest reported to date, suggests that selected patients with
relapse/progression after first AHCT can be rescued with current treatment modalities. However,
relapsed/progressed HL following AHCT still poses a therapeutic challenge, and prospective trials are
needed to determine the most appropriate approach in this setting.
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following AHCT, 30% to 60% of patients will
experience subsequent relapse or disease progression
depending on well-recognized adverse factors (chemo-
refractory disease, advanced stage, International Prog-
nostic Scoring System score, etc.) [1-7]. Until the last
decade, the clinical course of such patients was
believed to be extremely poor, with a median survival
post relapse/progression of less than a year [8,9].
Whereas the main therapeutic strategies still rely on
radiotherapy and chemotherapy (at conventional or
high doses plus hematopoietic cell support), there
have been essential advances both in treatment modal-
ities (new therapeutic agents such as gemcitabine,
vinorelbine, and reduced-intensity conditioning
[RIC] regimens for allogeneic HCT) as well as in the
supportive care of patients [10-17]. Consequently,
the outcome of patients with relapsed or progressed
disease following AHCT appears to have improved,
and recent retrospective studies have shown that the
median survival post AHCT failure may exceed
2 years in specific patients’ groups [13,14,18,19].451
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of heavily pretreated patients remains unclear
because the published data is limited.
In this multicenter retrospective study, we in-
tended to determine the factors that potentially influ-
enced the outcome in 126 patients who experienced
relapse or progression of disease following their first
AHCT for HL.METHODS
Five transplant centers from Greece, all members
of the European Group for Blood and Marrow Trans-
plantation, are participants in this retrospective analy-
sis. The study is not a European Group for Blood and
Marrow Transplantation analysis and was approved by
the institutional review board of each center. All
patients had already signed the authorized informed
consent for the anonymous use of their records for
scientific purposes. The evaluated patients had pro-
ceeded to AHCT for relapsed or primary refractory
disease and were treated according to each center’s
policy with respect to salvage treatment and stem cell
collection. For the vast majority of patients, the stan-
dard high doses of BiCNU, etoposide, Cytarabine
(Ara-C), andmelphalan were administered as a prepar-
ative regimen, whereas all patients received antimicro-
bial, antifungal, and antivirus agents as supportive care
during the early posttransplantation period.
Statistical Analysis
Time to relapse or progression post AHCT was
defined as the time from stem cell infusion to docu-
mented disease recurrence. Survival curves were calcu-
lated from the time of relapse/progression after first
AHCT using the Kaplan-Meier method, and statisti-
cally significant differences among different groups
were estimated using the log-rank test. To assess the
independence of the analyzed factors for survival rates,
we used the multivariate Cox regression analysis. Both
univariate and multivariate analyses were performed
using the SPSS version 18.0 software package (SPSS,
Inc., Chicago, IL), and a P value of\.05 was consid-
ered as the limit of statistical significance.Patients’ Characteristics
Between September 1991 and January 2010, a total
of 376 consecutive patients underwent AHCT, and
126 (33.5%) of them with relapsed or progressed dis-
ease post autografting were included in the present
analysis Fifty-two were females and 74 males, with
a median age at the time of transplant of 28.8 (range:
13-66) years. Among the 76 patients who had a relapse,
disease recurrence was confirmed by biopsy for the
majority of them (44 of 76, 58%), especially for thosewho experienced late relapse post AHCT. In 50 pa-
tients, the disease was considered progressed or refrac-
tory and was assessed by clinical criteria and imaging
tests (computed tomography [CT] or/and positron
emission tomography [PET] scans). Stable disease
post transplant according to CT scan criteria, but
with a positive PET scan, was also considered as re-
fractory disease.
With reference to treatment before the first
AHCT, 47 (37%) patients had received no more than
2 lines of therapy, whereas 79 (63%) had received 3
or more. The induction therapy and the chemotherapy
for stem cell mobilization were included in the lines of
therapy before AHCT. The disease had proven to be
chemosensitive (clinical response .50%) in 48 (38%)
patients, whereas in 78 (62%) it was chemorefractory.
At the time of the first transplantation, 9 patients
(7%) were in complete remission (CR), whereas 56
(44%) had detectable stage I to II and 60 (48%) had
stage III to IV disease. B-symptoms were present in
29 (23%) patients. Data on disease stage at the time
of transplantation was lacking in 1 patient. Fifty-three
patients had received radiotherapy either before
AHCTor as adjuvant treatment post AHCT (Table 1).RESULTS
The median follow-up was 30 (range: 2.1-200.6)
months for the entire group of patients and 43 (range:
5-200.6) months for the patients surviving by the time
of the analysis.
Twenty-three patients experienced disease relapse
or progression up to year 2000, whereas 103 experi-
enced relapse from 2000 onwards. The median time
for relapse or progression was 5 (range: 0.5-132)
months. In 75 (60%) patients, the disease relapsed/pro-
gressed within the first 6 months, in 17 (13%) within 6
to 12 months, and in 34 (27%) within more than 12
months post AHCT. At the time of disease recurrence,
17 (13%) patients presentedwith stage I, 36 (29%)with
stage II, 14 (11%) with stage III, and 59 (47%) with
stage IVdisease,whereas 27 (21%) of themexperienced
B-symptoms. New disease sites were noticed in 59 of
126 (47%) patients. Adequate data to calculate the
International Prognostic Scoring System was available
only in 40 of 126 patients (32%) (Table 1).
Treatment for Relapse or Progression
Themajority of patients, 88 of 126 (70%), received
chemotherapy (single agent or various combinations)
at conventional doses plus or without irradiation.
Radiation-only was the choice of treatment in 11
(9%) individuals, 9 of whom were staged as IA or IIA.
A total of 19 (15%) patients underwent a second
HCT. Fourteen received an allogeneic transplant
with a RIC regimen. All but 2 allografted patients had
Table 1. Patient’s Characteristics
Evaluated patients 126
Sex (female/male) 52/74
Disease status at AHCT
Refractory 78 (62%)
Sensitive 48 (38%)
Lines of therapy before AHCT
#2 47 (37%)
>2 79 (63%)
Age at relapse 29 (13-66) years
Time to relapse/progression after AHCT 5 (0.5-132) months
<6 months 75 (60%)
6-12 months 17 (13%)
>12 months 34 (27%)
Stage
I 17 (13%)
II 36 (29%)
III 14 (11%)
!V 59 (47%)
B-symptoms 27 (21%)
New sites 59 (47%)
Treatment post relapse/progression
Chemotherapy ± irradiation (R/T) 88
Gemcitabine-based 47
MOPP or ChLOPP 14
BELP or CELP 7
ABVD 3
Other agents in various combinations 17
R/Tonly 11
Second HCT 19
AHCT 5
AlloHCT (reduced-intensity regimen) 14
No treatment 10
PET-scan (+) without any clinical evidence
of disease
6
Refused any therapy 4
AHCT indicates autologous hematopoietic cell transplantation; MOPP,
mechlorethamine/vincristine/procarbazine/prednisone; ChLOPP, chlor-
ambucil/vincristine/procarbazine/prednisone; CELP, CCNU/etoposide/
chlorambukil/prezolon; BELP, BiCNU/etoposide/chlorambukil/prezolon;
ABVD, Adriamycin, Bleomycin, Viznblastine, Dacarbazine; PET, positron
emission tomography.
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stem cell transplantation as a debulking treatment. Five
patients underwent a second AHCT after successful
stem cell remobilization with chemotherapy and
granulocyte colony stimulating factor administration.
In 6 patients, disease presence was inferred by
a positive PET scan. It should be noted that biopsies
were not doable, as there were neither clinically nor
radiologically evident affected sites. As they had no
other clinical sign of disease presence, they did not
receive treatment (watch-and-wait approach). Four
patients declined any therapy and received palliative
treatment only (Table 1).
Disease Response
Among the 116 treated patients, 71 (61%) re-
sponded: 44 (38%) achieved a complete and 27
(23%) a partial remission (PR). Seventy-eight of the
116 had undergone AHCT for chemorefractory dis-
ease, and 40 (51%) of them achieved a new response
(CR: 19 and PR: 21). For the rest of the 48 treated pa-
tients who had received AHCT for chemosensitive dis-ease, a new response was obtained in 31 (64%): 25
achieved CR, while 6 achieved PR. Factors that inde-
pendently predicted any response (complete or partial)
were: disease chemosensitivity prior to an interval of
more than 12 months from first AHCT to disease re-
lapse/progression, age, absence of B-symptoms, and
advanced stage (III-IV) at the time of relapse/progres-
sion. Female sex demonstrated a trend to significant
association with response (P 5 .06).Factors That Influenced Survival
Currently, 53 of 126 patients are alive for a median
of 32 (range: 0.5-148, 95% confidence interval 22.8-
41.1) months post relapse/progression, and 44 of them
remain progression-free. In the multivariate (Cox re-
gression) model, included variables were the interval
from the first AHCT to relapse/progression, time pe-
riod of relapse/progression (before or after 2000),
patient sex and age, disease stage, presence of B-symp-
toms, new sites at the time of relapse/progression, che-
mosensitivity before the first AHCT, response to the
treatment post relapse/progression, and the type of
treatment. Karnofsky status was not incorporated in
the statistical model because the vast majority of
patients in our series had a score of approximately 90%.
The following factors independently influenced
the survival rates:
Interval between first allogeneic stem cell transplanta-
tion and relapse/progression
Estimated median survival was 27 versus 71
months (P\ .0001), with time to relapse/progression
#12 months and .12 months post AHCT
respectively (Table 2 and Figure 1A).
Response to treatment following relapse/progression
Patients who responded to salvage treatment for
disease recurrence post AHCT achieved an approxi-
mately 5-fold higher median survival compared with
those who had no response (70 versus 13 months,
P 5 .001). (Table 2 and Figure 1B).
B-symptoms
The absence of B-symptoms at the time of relapse
or progression strongly correlated with better survival
rates. The median survival was 14 versus 41months for
patients with and without presence of B-symptoms, re-
spectively (P 5 .04) (Table 2 and Figure 1C).
Type of treatment
According to the most recent follow-up data, 34 of
88 (39%) patients who were treated with chemother-
apy plus or without irradiation remain alive.
Six of 11 patients with limited disease stages who
received irradiation-only have been alive for a median
of 50 months.
Among the 19 patients who underwent a second
stem cell transplantation, 7 (5 allografted and 2 auto-
grafted) are currently alive.
Table 2. Multivariate Analysis in Terms of Survival Post Relapse/Progression following Autologous Hematopoietic Cell
Transplantation
Factor Hazard ratio Significance (P)
95% CI
Lower Upper
Interval >12 months from AHCT to relapse/progression 1.56 <0.0001 0.10 0.43
Absence of B-symptoms 0.54 0.04 0.3 0.06
Response to treatment post relapse/progression 1.982 0.0001 3.86 13.64
Female sex 0.59 0.07 0.33 1.03
Stage #II 0.14 0.7 0.5 2.3
Age <45 years 0.43 0.26 0.29 1.39
Absence of new locations 0.31 0.26 0.43 1.25
Chemosensitivity before first AHCT 0.39 0.18 0.38 1.02
Type of therapy 0.01 0.9 0.69 1.39
Year of relapse >2000 0.3 0.2 0.4 1.26
Risk group* 1.034 0.001 1.56 5.03
CI indicates confidence interval; AHCT, autologous hematopoietic cell transplantation.
In multivariate analysis, the interval >12 months from AHCT to relapse/progression, the absence of B-symptoms, the response to treatment post re-
lapse/progression, and the favorable risk group (0-1 adverse factors) emerged as significant factors for increased survival rates.
*The risk group was assessed according to the proposed prognostic model.
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offered to patients in advanced disease stages (chemo-
therapy 6 irradiation versus second stem cell trans-
plantation), we noted that the median survival was 40
months for retransplanted patients versus 28 months
for patients who were treated with chemotherapy6 ir-
radiation. However, this benefit of a second HCT on
survival did not reach statistical significance either in
univariate or in multivariate analysis, probably because
of the small number of patients who underwent a sec-
ond HCT (Table 2 and Figure 1D).Figure 1. Overall survival from relapse/progression post AHCTaccording to
(B), B-symptoms presence (C), and type of treatment (D).Interestingly, all 6 patients who had only positive
PET scan findings as the sole evidence of disease
recurrence and did not receive any treatment (watch-
and-wait approach) have remained alive without
further disease progression for a median of 17 (range:
8-54) months.
Year of relapse/progression
Only 4 of 23 (17%) patients who relapsed/pro-
gressed before 2000 are currently alive. On the other
hand, 49 of 103 (47%) patients for whomACHT failed
are alive. However, this difference had no statistical: interval from AHCT to relapse/progression (A), response to treatment
months
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Figure 2. Survival rates from relapse/progression post AHCTaccord-
ing to our proposed prognostic model. Patients with 0 to 1 unfavorable
factors (red line) showed more significantly higher survival rates than
those with 2 to 3 unfavorable factors (blue line).
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analysis.
A prognostic model
In a multivariate Cox regression model, we investi-
gated the factors that might have a predictive impact
on survival at the time of relapse or progression. Obvi-
ously, we incorporated neither the type of treatment
for relapse/progression nor the response to treatment
in this model. Three factors proved to be significant
in both univariate and multivariate analysis: interval
of #12 months from the first AHCT to relapse/pro-
gression, presence of B-symptoms at the time of re-
lapse/progression, and no chemosensitivity of disease
before the first AHCT. Consequently, 54 patients
with 0 to 1 unfavorable factors at the time of relapse/
progression were characterized as low-risk, and 72
with 2 to 3 unfavorable factors were characterized as
high-risk. Low-risk patients reached a median survival
of 70 months compared to 17 months for high-risk pa-
tients (P\ .001). The risk group also proved to be
a highly significant predictive factor for survival dura-
tion post relapse/progression (Table 2 and Figure 2).DISCUSSION
During the lastdecade, therehavebeen several treat-
ment options available toHLpatients forwhom the first
AHCT failed. However, there is limited data regarding
the optimal treatment choice and the contributing fac-
tors toward a favorable long-term outcome.
To our knowledge, this multicenter retrospective
study of 126 patients represents the largest series of
relapsed/progressed patients following the firstAHCT to date, including different treatment ap-
proaches as well. Notwithstanding the caveats of a ret-
rospective study, no randomized trials have addressed
the issue of the management of this heavily pretreated
population.
In our study, the median survival for the entire
cohort of patients was 32months, which is substantially
better than initially reported and in line with the results
of recently published studies. It is reasonable therefore
to assume that the currently available treatment
options (new agents and allogeneic transplants with
reduced indencity regimens) as well as improvements
in supportive care have changed the perspective of
patients with recurrent HL following AHCT
[8,9,13,14,18,19]. Another notable point of this study
is the finding that approximately 50% of the patients
(40 of 78), who had undergone AHCT for
chemorefractory disease, obtained a new response,
after relapse/progression, and, 19 of them (24%)
achieved a CR. Apart from the previously mentioned
reasons for these encouraging results, another
possible explanation may be that AHCT actually
alters the biologic behavior of malignant cells,
making them more susceptible to chemotherapy.
According to published studies, variable factors
have been correlated to the outcome of relapsed/pro-
gressed HL post AHCT. This may reflect the hetero-
geneity of the existing studies in terms of patient and
disease characteristics, treatment approaches, and
other variables. Time from AHCT to relapse or pro-
gression longer than 6 to 12 months, disease chemo-
sensitivity, and second allogeneic transplantation
have been suggested as favorable factors for long-
term survival [4-7].
The unequivocal finding of all studies is that dis-
ease refractoriness has a powerful adverse impact on
survival. Our results confirm the above principle by
demonstrating that an interval shorter than 12 months
from AHCT to relapse/progression, lack of response
to salvage treatment post AHCT, and B-symptoms
at relapse/progression are unfavorable prognostic fac-
tors for long-term survival because they constitute di-
rect or indirect indicators of refractory disease.
Second transplantation, especially from an alloge-
neic donor, has emerged as a viable and a promising
option for patients in whom the first AHCT, fails, par-
ticularly in the era of RIC regimens [13-18].
In our study, the retransplanted patients achieved
a median survival of 40 months as opposed to only
28 months in those who were treated with conven-
tional doses of chemotherapy plus or without radia-
tion. However, this difference did not reach
statistical significance. By contrast, in other studies,
allogeneic transplantation was found to be a favorable
prognostic factor for achieving long-term survival
[13-15,18]. A possible explanation could be that, in
our study, the number of patients who proceeded to
456 Biol Blood Marrow Transplant 18:451-457, 2012P. Kaloyannidis et al.a second transplantation was small (19 patients). On
the other hand, one must keep in mind that those
studies are retrospective and therefore liable to
selection biases.
A clinical observation that merits consideration is
that the 6 patients with a repeated positive PET scan
after their first AHCT and no additional evidence of
disease did not receive any treatment, and interestingly
showed no progression with a median follow-up of 17
(range: 8-54) months. Several groups have published
data suggesting a predictive value of a positive PET
scan for an unfavorable outcome because of imminent
relapse. However, recent studies have thrown doubt
upon the unquestioned specificity of the PET scan in
predicting relapse post AHCT [20-24]. In a recent
study, Lambert et al. [20] reported that a positive
PET scan predicted relapse before CT scans in one-
half of the relapsed cases. However, they also noted
that in 2% of cases, the positivity of the PET scan
was attributed to causes other than disease, and the
fluorine-18-deoxyglucose (FDG) uptake became grad-
ually normal over time. In the previously mentioned 6
patients, no active infection or inflammatory condi-
tions were recorded at the time of the positive PET
scan. Nevertheless, it is well known that HL may re-
main ‘‘dormant’’ for prolonged periods, and, therefore,
close monitoring is probably the most reliable
approach.
The timely recognition of patients whomight have
a worse outcome following relapse/progression after
the first AHCT for HL is of great importance in clin-
ical practice. To address the this issue, we explored the
factors that influence survival in advance of any treat-
ment for relapse. We identified 3 independent prog-
nostic factors (interval of\12 months from the first
AHCT to relapse or progression, presence of B-symp-
toms at the time of relapse/progression, and no
chemosensitivity of disease before the first AHCT),
and we created a prognostic model based on those fac-
tors. The estimated median survival for low-risk pa-
tients (with 0-1 unfavorable factors) was quite
encouraging, approaching 6 years regardless of the
type of treatment. This model exhibited a high pre-
dictability value in terms of survival rates in univariate
and multivariate analysis, probably because of its abil-
ity to grade disease refractoriness. Nevertheless, its
utility needs to be confirmed by prospective trials.
In conclusion, our multicenter study comprising
the largest series to date, confirms that a considerable
proportion of patients who relapse or progress after
their first AHCT can attain very promising long-
term survival. According to our proposed model, this
group consists of patients in whom the disease still re-
tains chemosensitivity to treatment. Our study did not
reveal any significant advantage in outcome in relation
to the type of treatment. By the time prospective trials
assess the value of different treatment options, themanagement of relapsed/progressed HL after the first
AHCT should be individualized according to patient
and disease characteristics.ACKNOWLEDGMENTS
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